The Use of Biological Therapies in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Current State of Knowledge
Open Access
- 26 July 2026
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5837
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease with a complex pathogenesis that significantly affects patients’ quality of life. Type 2 inflammation plays a dominant role in its course and is associated with the activation of immune pathways involving interleukins IL-4, IL-5 and IL-13, eosinophils, and immunoglobulin E. Standard treatment methods, including corticosteroids and surgical interventions, despite their proven efficacy, often fail to provide sustained disease control and are associated with a high rate of recurrence. The aim of this review is not only to summarize the available evidence on biological therapies in CRSwNP, but also to critically evaluate their current position within treatment algorithms, with particular emphasis on patient selection, integration with endoscopic sinus surgery, comparison of available biologic mechanisms, and remaining challenges in personalized treatment strategies. The paper discusses available monoclonal antibodies, such as dupilumab, omalizumab, mepolizumab, and benralizumab, which act by selectively inhibiting key mediators of type 2 inflammation. Analysis of clinical trial results indicates that biological therapies lead to a significant reduction in nasal polyp size, improvement in nasal patency, restoration of olfactory function, and enhancement of quality of life as measured by the SNOT-22 scale. Furthermore, they demonstrate a favourable safety profile and may represent an effective therapeutic option for patients with severe, treatment-resistant disease, particularly in cases with coexisting eosinophilic asthma. Biological therapies represent a breakthrough in the treatment of CRSwNP and align with the concept of personalised medicine. Their role in clinical practice continues to expand; however, further research is required to optimise patient selection and assess long-term treatment outcomes.Keywords
This publication has 136 references indexed in Scilit:
- The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With PolyangiitisArthritis & Rheumatology, 2025
- Which Is the Best Biologic for Nasal Polyps: An Updated Network Meta‐AnalysisClinical and Translational Allergy, 2025
- Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or MepolizumabACR Open Rheumatology, 2025
- Targeting thymic stromal lymphopoietin in nasal type 2 inflammationEye & ENT Research, 2025
- Benralizumab and the integrated management of co‐morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polypsClinical and Translational Allergy, 2025
- Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experienceInternational Forum of Allergy & Rhinology, 2024
- Adverse events for biologics in patients with CRSwNP: A meta‐analysisClinical and Translational Allergy, 2022
- The roles of eosinophils and interleukin‐5 in the pathophysiology of chronic rhinosinusitis with nasal polypsInternational Forum of Allergy & Rhinology, 2022
- Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational StudyArthritis & Rheumatology, 2021
- Functional endoscopic sinus surgery for chronic rhinosinusitisCochrane Database of Systematic Reviews, 2006